The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...
While there's no cure yet for Alzheimer's, researchers are finally making more progress in better understanding the disease ...
FDA could also establish a more clear and transparent structure for interactions between agency staff and companies, which ...
From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...
the abject failure of Alzheimer's drug and former blockbuster hope Aduhelm (aducanumab) in the market, setbacks in its R&D pipeline, and leadership changes. Analysts at Jefferies suggested earlier ...
Cheryl, 75, has lived with Alzheimer’s disease for nearly five years, but it hasn’t all been bleak. John, 76, said he had some hope for about 18 months when Cheryl was enrolled in a clinical trial for ...
Why did Latrepirdine Fail in Phase III Studies? There are several plausible explanations for the failure of latrepirdine in Phase III trials despite promising Phase II data. The three most likely ...
Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...
The WVU Rockefeller Neuroscience Institute is providing patients greater statewide and regional access to a groundbreaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback